Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB059872 in advanced malignancies
NCT02712905Phase 2Terminated
- Sponsor
- Incyte
- Start
- May 2016
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of incb059872 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), small cell lung cancer (SCLC), myelofibrosis (MF), Ewing sarcoma, sponsored by Incyte. Started May 2016; status: terminated.
02
Drugs
incb059872
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)small cell lung cancer (SCLC)myelofibrosis (MF)Ewing sarcoma
Beyond the preview
Go deeper on NCT02712905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712905.